Article

High tumor mutational burden predicts survival and responses to ICI immunotherapy in a cancer-dependent manner

2023-08-29

Abstract excerpt

<h4>Objective</h4> High tumor mutational burden (TMB) is a promising biomarker for patients with immunotherapy in certain types of solid tumors. This article focuses on exploring possible universally optimal cutoffs of TMB for predicting immune checkpoint inhibitors (ICIs) response and prognosis for eight types of cancers. <h4>Methods</h4> The present study collected eight types of tumors including 2767 patients r...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0ac47720-6c72-5727-bf45-4da6bca6512e
DOI: 10.1101/2023.08.29.23294599

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

High tumor mutational burden predicts survival and responses to ICI immunotherapy in a cancer-dependent mannerDOI 10.1101/2023.08.29.23294599Read

TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types.Semantic proximity Read

The Impact of TMB on Immunotherapy Protocols: A Comprehensive Analysis of Four Major CancersSemantic proximity Read

Evaluating Tumour Mutational Burden as a Key Biomarker in Personalized Cancer Immunotherapy: A Pan-Cancer ApproachSemantic proximity Read

The association between tumor mutational burden and prognosis is dependent on treatment context.Semantic proximity Read

Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkersSemantic proximity Read

A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.Semantic proximity Read

A Systematic Review and Meta-Analysis of the Impact of Tumour Mutation Burden on Survival Outcomes in Solid TumoursSemantic proximity Read

Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better.Semantic proximity Read

Interplay between Tumor Mutational Burden and Mutational Profile and its effect on overall survival: A Post Hoc Analysis of Metastatic Patients Treated with Immune Checkpoint InhibitorsSemantic proximity Read

A mutational signature and significantly mutated driver genes associated with immune checkpoint inhibitor response across multiple cancers.Semantic proximity Read

The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors.Semantic proximity Read

Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore.Semantic proximity Read